// App-Quantinova.ai

OC3.6 : 11β-Hydroxysteroid dehydrogenase type 1 inhibition protects against the development of adverse metabolic and bone effects of prednisolone: A randomized, double-blind, placebo-controlled trial

Researchers

Presenter

  • Nantia Othonos

Principal Investigators

  • Riccardo Pofi

  • Anastasia Arvaniti

  • Andrew Whittaker

  • Paul Stewart

  • Ruth Coleman

  • Olorunsola Agbaje

  • Joanne Milton

  • Rury Holman

  • Jeremy W Tomlinson

Medical Centers

  • University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, United Kingdom

  • Sapienza University of Rome, Dept. Experimental Medicine, Roma, Italy, Italy

  • Oxford Brookes University, Department of Biological and Medical Sciences, Oxford, United Kingdom

  • Astra Zeneca, Cambridge, United Kingdom

  • University of Leeds, School of Chemistry, Leeds, United Kingdom

  • University of Oxford, Diabetes Trial Unit, Oxford, United Kingdom

Locations

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Bone gamma-carboxyglutamic acid-containing protein

  • Body mass index

Drug/Treatment

  • Glucocorticoid

  • Prednisolone

  • Prednisone

  • AZD-4017

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved